Treatment of Acute Interstitial Cystitis Flare
For an acute IC/BPS flare, immediately implement increased fluid intake (water), bladder analgesic instillation with lidocaine-based rescue solution (heparin or pentosan polysulfate combined with sodium bicarbonate and lidocaine), and oral analgesics, while having the patient avoid known dietary and activity triggers.
Immediate Flare Management
The acute flare requires rapid symptom control through multiple simultaneous interventions:
First-Line Acute Interventions
- Increase water/fluid intake - This is the most commonly used strategy by patients (74.5% report using this) and provides immediate dilutional relief 1
- Bladder rescue instillation - Use an anesthetic therapeutic relief solution containing:
- Lidocaine (local anesthetic)
- Heparin sulfate OR pentosan polysulfate
- Sodium bicarbonate (alkalinization)
- This combination provides rapid pain relief for moderate to severe flares 2
Concurrent Oral Medications
- Analgesics - Standard pain medications for immediate relief
- Antispasmodics - To reduce bladder spasm and urgency
- Consider short-term antihistamines if not already on maintenance therapy 2
Trigger Avoidance During Flare
Patients must immediately eliminate known triggers 1:
Dietary triggers to avoid:
- Citrus fruits
- Tomatoes
- Spicy foods
- Alcoholic beverages
- Caffeinated beverages
Activity triggers to avoid:
- Prolonged sitting/driving
- Sexual activity (if this is a known trigger)
- Tight clothing
- High-heeled shoes
Other triggers:
- Stress (implement stress reduction techniques)
- Urinary tract infections (obtain culture if suspected)
Treatment Framework Based on Current Guidelines
The 2022 AUA guidelines 3 emphasize that IC/BPS treatment must be individualized but should start with non-surgical approaches except in patients with Hunner lesions who require cystoscopic intervention. The guidelines categorize treatments into:
- Behavioral/non-pharmacologic
- Oral medicines
- Bladder instillations
- Procedures
- Major surgery (last resort)
Concurrent, multi-modal therapies should be offered rather than sequential single-agent trials 3.
Important Clinical Caveats
Pentosan Polysulfate Warning
While PPS has historically been used as foundation therapy 2, the 2022 guidelines now include statements about potential adverse events from pentosan polysulfate 3. Discuss risks versus benefits if considering this for maintenance after flare resolution.
Hunner Lesions Require Different Approach
If the patient has documented Hunner lesions on prior cystoscopy, complete transurethral ablation of lesions should be prioritized 4. These patients represent a distinct phenotype requiring endoscopic intervention rather than just medical management.
Timing of Flares
Flares most commonly occur in afternoon or evening 1, which can guide timing of preventive measures and rescue medication availability.
Rule Out Mimics
Even in established IC/BPS patients, acute worsening requires consideration of:
- Urinary tract infection (obtain culture)
- Bladder cancer (especially in smokers or those with hematuria) 3, 5
- Urinary tuberculosis in appropriate clinical contexts 5
Evidence Quality Note
The most recent systematic review and network meta-analysis (2024) 6 found that no single treatment demonstrated significant improvement across all outcome measures, supporting the multimodal approach. Instillation and intravesical injection showed statistically significant improvements in pain and urgency in pairwise comparisons, reinforcing the use of bladder instillations for acute flares.
Female patients and those with somatic sensory hypersensitivity typically require more therapies and report more triggers 1, suggesting these populations need more aggressive multimodal acute management.